Biosergen AS (BIOSGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biosergen AS (BIOSGN) has a cash flow conversion efficiency ratio of -0.954x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-7.75 Million ≈ $-833.70K USD) by net assets (Skr8.12 Million ≈ $873.52K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BIOSGN defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Biosergen AS - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Biosergen AS's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Biosergen AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biosergen AS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Binakarya Jaya Abadi Tbk PT
JK:BIKA
|
-0.043x |
|
Mantex AB
ST:MANTEX
|
-1.685x |
|
CAP-EX IRON ORE
F:X0V
|
-0.025x |
|
Winsome Yarns Limited
NSE:WINSOME
|
-0.046x |
|
Bastion Minerals Ltd
AU:BMO
|
-0.347x |
|
Melar Acquisition Corp. I Warrant
NASDAQ:MACIW
|
N/A |
|
Noratis AG
XETRA:NUVA
|
0.070x |
|
McLaren Resources Inc
F:3ML
|
0.398x |
Annual Cash Flow Conversion Efficiency for Biosergen AS (2019–2025)
The table below shows the annual cash flow conversion efficiency of Biosergen AS from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see BIOSGN company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr8.12 Million ≈ $873.52K |
Skr-35.53 Million ≈ $-3.82 Million |
-4.378x | -1193.49% |
| 2024-12-31 | Skr49.14 Million ≈ $5.29 Million |
Skr-16.63 Million ≈ $-1.79 Million |
-0.338x | +97.80% |
| 2023-12-31 | Skr2.12 Million ≈ $227.72K |
Skr-32.60 Million ≈ $-3.51 Million |
-15.408x | -1092.92% |
| 2022-12-31 | Skr22.79 Million ≈ $2.45 Million |
Skr-29.44 Million ≈ $-3.17 Million |
-1.292x | +30.77% |
| 2021-12-31 | Skr20.23 Million ≈ $2.18 Million |
Skr-37.75 Million ≈ $-4.06 Million |
-1.866x | -544.61% |
| 2020-12-31 | Skr-10.92 Million ≈ $-1.18 Million |
Skr-4.58 Million ≈ $-493.31K |
0.420x | -14.94% |
| 2019-12-31 | Skr-4.69 Million ≈ $-504.90K |
Skr-2.31 Million ≈ $-249.07K |
0.493x | -- |
About Biosergen AS
Biosergen AB (publ), a biotech company, develops antifungal products. Its lead product is BSG005, an antifungal drug candidate for the treatment of invasive fungal infections in immunocompromised patients, including AIDS, cancer, and transplant recipients. The company was founded in 2004 and is based in Solna, Sweden.